替吉奥联合多西他赛治疗晚期胃癌的疗效观察  

To observe the curative effect of S-1 combined with docetaxel in the treatment of advanced gastric cancer

作　　者：何灵慧[1] 谭清和[1] 王建红[1] 朱亚芳[1] 

机构地区：[1]南通市肿瘤医院,江苏南通226361

出　　处：《中国卫生产业》2013年第30期22-23,共2页China Health Industry

摘　　要：目的观察评价替吉奥联合多西他赛化疗治疗晚期胃癌的近期疗效和毒副反应。方法选择我院2008年1月—2013年6月收治的24例无法手术及放疗的晚期胃癌患者,给予替吉奥40 mgbid/m^2d1-14,多西他赛40 mg/m^2d1联合化疗,每21 d为1个周期,每完成2个周期评价疗效。每个周期化疗后评价毒副反应。结果 24例总有效率为41.7%,疾病控制率70.8%。主要毒副反应为骨髓抑制、胃肠道反应等,均为轻、到中度。结论替吉奥联合多西他赛治疗晚期胃癌疗效确切,毒副反应较低,值得临床推广及进一步研究。Objective Objective To observe the efficacy and toxicity 0f docetaxel and S-1 combined evaluation of chemotherapy in the treatment of advanced gastric cancer.Methods In our hospital from 2008 January to 2013 June were treated 24 cases of no operation and radiotherapy in patients with advanced gastric cancer, give 40mg bid/m2 dl-14 40mg/m2 s-l, docetaxel chemotherapy combined with D1, every 21 d for 1 cycles, each completed 2 cycles efficacy evaluation. Toxicity evaluation of each cycle of chemotherapy.Results Of the 24 cases, the total effective rate was 41.7%, disease control rate of 70.8%.The main side effects were bone marrow suppression, gastrointestinal reactions were mild to moderate.Conclusion S-1 combined with docetaxel exact curative effect in the treatment of advanced gastric cancer, toxicity is low, is worth the clinical promotion and further research.

关 键 词：晚期胃癌 替吉奥 多西他赛 联合化疗 

分 类 号：R735[医药卫生—肿瘤]